S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Stock market today: Asian shares mixed as Japan business confidence rises and US shutdown is averted
Buy THIS stock before Taiwan is attacked (Ad)
Federal student loan payments are starting again. Here's what you need to know
Bank of Japan survey shows manufacturers optimistic about economy
66,000% upside on tiny biotech? (Ad)
Facing increasing pressure from customers, some miners are switching to renewable energy
Grant program for Black women entrepreneurs blocked by federal appeals court
66,000% upside on tiny biotech? (Ad)
The death toll in a collapsed gold mine in Zimbabwe expected to rise to 13, vice president says
UK Treasury chief says he'll hike the minimum wage but rules out tax cuts while inflation stays high
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Stock market today: Asian shares mixed as Japan business confidence rises and US shutdown is averted
Buy THIS stock before Taiwan is attacked (Ad)
Federal student loan payments are starting again. Here's what you need to know
Bank of Japan survey shows manufacturers optimistic about economy
66,000% upside on tiny biotech? (Ad)
Facing increasing pressure from customers, some miners are switching to renewable energy
Grant program for Black women entrepreneurs blocked by federal appeals court
66,000% upside on tiny biotech? (Ad)
The death toll in a collapsed gold mine in Zimbabwe expected to rise to 13, vice president says
UK Treasury chief says he'll hike the minimum wage but rules out tax cuts while inflation stays high
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Stock market today: Asian shares mixed as Japan business confidence rises and US shutdown is averted
Buy THIS stock before Taiwan is attacked (Ad)
Federal student loan payments are starting again. Here's what you need to know
Bank of Japan survey shows manufacturers optimistic about economy
66,000% upside on tiny biotech? (Ad)
Facing increasing pressure from customers, some miners are switching to renewable energy
Grant program for Black women entrepreneurs blocked by federal appeals court
66,000% upside on tiny biotech? (Ad)
The death toll in a collapsed gold mine in Zimbabwe expected to rise to 13, vice president says
UK Treasury chief says he'll hike the minimum wage but rules out tax cuts while inflation stays high
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Stock market today: Asian shares mixed as Japan business confidence rises and US shutdown is averted
Buy THIS stock before Taiwan is attacked (Ad)
Federal student loan payments are starting again. Here's what you need to know
Bank of Japan survey shows manufacturers optimistic about economy
66,000% upside on tiny biotech? (Ad)
Facing increasing pressure from customers, some miners are switching to renewable energy
Grant program for Black women entrepreneurs blocked by federal appeals court
66,000% upside on tiny biotech? (Ad)
The death toll in a collapsed gold mine in Zimbabwe expected to rise to 13, vice president says
UK Treasury chief says he'll hike the minimum wage but rules out tax cuts while inflation stays high
NASDAQ:SCYX

SCYNEXIS (SCYX) Stock Forecast, Price & News

$2.28
-0.02 (-0.87%)
(As of 09/29/2023 08:53 PM ET)
Compare
Today's Range
$2.25
$2.47
50-Day Range
$1.93
$3.65
52-Week Range
$1.15
$3.87
Volume
354,900 shs
Average Volume
839,075 shs
Market Capitalization
$84.77 million
P/E Ratio
2.71
Dividend Yield
N/A
Price Target
$11.40

SCYNEXIS MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
400.0% Upside
$11.40 Price Target
Short Interest
Healthy
3.66% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.38mentions of SCYNEXIS in the last 14 days
Based on 19 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
-91.32%
From $2.65 to $0.23 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.20 out of 5 stars

Medical Sector

426th out of 968 stocks

Pharmaceutical Preparations Industry

185th out of 450 stocks


SCYX stock logo

About SCYNEXIS (NASDAQ:SCYX) Stock

SCYNEXIS, Inc., a biotechnology company, develops products for the treatment of fungal infections in the United States. It offers BREXAFEMME for the treatment of vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of various fungal infections, including invasive candidiasis, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It has research collaborations with Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC to develop and commercialize rights for ibrexafungerp. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.

SCYX Price History

SCYX Stock News Headlines

BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
Head-To-Head Review: SCYNEXIS (NASDAQ:SCYX) & Alkermes (NASDAQ:ALKS)
Nasdaq Turns Higher; SCYNEXIS Shares Plunge
SCYNEXIS (SCYX) Skyrockets 134% Year to Date: Here's Why
SCYNEXIS (SCYX) Receives a Buy from Maxim Group
See More Headlines
Receive SCYX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for SCYNEXIS and its competitors with MarketBeat's FREE daily newsletter.

SCYX Company Calendar

Last Earnings
8/14/2023
Today
10/02/2023
Next Earnings (Estimated)
11/08/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SCYX
Employees
36
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$11.40
High Stock Price Forecast
$15.00
Low Stock Price Forecast
$8.00
Forecasted Upside/Downside
+400.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-62,810,000.00
Pretax Margin
32.71%

Debt

Sales & Book Value

Annual Sales
$5.09 million
Book Value
$0.10 per share

Miscellaneous

Free Float
35,540,000
Market Cap
$84.77 million
Optionable
Optionable
Beta
2.14
The Best High-Yield Dividend Stocks for 2023 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Mr. David Gonzalez Angulo M.D. (Age 58)
    CEO, Pres & Director
    Comp: $631.69k
  • Mr. Scott Sukenick J.D. (Age 45)
    Chief Legal Officer & Corp. Sec.
    Comp: $542.05k
  • Mr. Ivor Macleod CPA (Age 62)
    M.B.A., Chief Financial Officer
  • Debbie Etchison
    Exec. Director of Communications
  • Ms. Daniella Gigante
    VP of HR & Information Technology













SCYX Stock - Frequently Asked Questions

Should I buy or sell SCYNEXIS stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for SCYNEXIS in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SCYX shares.
View SCYX analyst ratings
or view top-rated stocks.

What is SCYNEXIS's stock price forecast for 2023?

4 brokers have issued 1-year target prices for SCYNEXIS's shares. Their SCYX share price forecasts range from $8.00 to $15.00. On average, they predict the company's stock price to reach $11.40 in the next year. This suggests a possible upside of 400.0% from the stock's current price.
View analysts price targets for SCYX
or view top-rated stocks among Wall Street analysts.

How have SCYX shares performed in 2023?

SCYNEXIS's stock was trading at $1.56 on January 1st, 2023. Since then, SCYX shares have increased by 46.2% and is now trading at $2.28.
View the best growth stocks for 2023 here
.

When is SCYNEXIS's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023.
View our SCYX earnings forecast
.

How were SCYNEXIS's earnings last quarter?

SCYNEXIS, Inc. (NASDAQ:SCYX) issued its quarterly earnings data on Monday, August, 14th. The company reported $2.46 EPS for the quarter, topping analysts' consensus estimates of $1.03 by $1.43. The business earned $131.45 million during the quarter, compared to the consensus estimate of $91.50 million. SCYNEXIS had a trailing twelve-month return on equity of 317.92% and a net margin of 32.71%.

When did SCYNEXIS's stock split?

SCYNEXIS's stock reverse split before market open on Friday, July 17th 2020. The 1-10 reverse split was announced on Thursday, July 16th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, July 16th 2020. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of SCYNEXIS own?
What is SCYNEXIS's stock symbol?

SCYNEXIS trades on the NASDAQ under the ticker symbol "SCYX."

How do I buy shares of SCYNEXIS?

Shares of SCYX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is SCYNEXIS's stock price today?

One share of SCYX stock can currently be purchased for approximately $2.28.

How much money does SCYNEXIS make?

SCYNEXIS (NASDAQ:SCYX) has a market capitalization of $84.77 million and generates $5.09 million in revenue each year. The company earns $-62,810,000.00 in net income (profit) each year or $0.84 on an earnings per share basis.

How can I contact SCYNEXIS?

SCYNEXIS's mailing address is 1 EVERTRUST PLAZA 13TH FLOOR, JERSEY CITY NJ, 07302. The official website for the company is www.scynexis.com. The company can be reached via phone at (201) 884-5485, via email at ikoffler@lifesciadvisors.com, or via fax at 201-884-5490.

This page (NASDAQ:SCYX) was last updated on 10/2/2023 by MarketBeat.com Staff

My Account -